Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Familial Adenomatous Polyposis (FAP)
Interventions: eRapa (encapsulated rapamycin), Placebo; Drug
Lead sponsor: Rapamycin Holdings Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 18
States / cities: Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Conditions: Pain, Cancer
Interventions: EN3267; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 17 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions: Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Postoperative
Interventions: PMI-150 (intranasal ketamine), Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Florence, Alabama • Sheffield, Alabama + 13 more

Conditions: Angelman Syndrome, Nervous System Diseases
Interventions: Betaine, Creatine, Metafolin, Vitamin B12; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Day to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Greenwood, South Carolina + 1 more

Conditions: Otherwise Healthy Overweight or Obese
Interventions: PHP-303, Placebo; Drug · Other
Lead sponsor: pH Pharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prader-Willi Syndrome
Interventions: Listening Project Protocol; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 13 Years to 25 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Brewster, Massachusetts

Conditions: Shoulder Arthroscopy, Knee Arthroscopy
Interventions: Sugar pill, Gabapentin, Clonidine; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronary Artery Disease
Interventions: Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more

Conditions: Acute Myeloid Leukemia
Interventions: IMGN779; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • Boston, Massachusetts • Albuquerque, New Mexico + 4 more

Conditions: Epilepsy
Interventions: diazepam nasal spray; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more

Conditions: Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions: Thrombosomes; Biological
Lead sponsor: Cellphire Therapeutics, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more

Conditions: Solid Tumors
Interventions: MSB0011359C; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 36
States / cities: Tucson, Arizona • Escondido, California • Sacramento, California + 32 more

Conditions: Multiple Sclerosis, Spinal Cord Injury, Chronic Pain, Other and Unspecified Amputation Stump Complications, Muscular Dystrophies, Low Back Pain
Interventions: Pain Self-Management Intervention #1, Pain Self-Management Intervention #2, Pain Self-Management Intervention #3, Pain Self-Management Intervention #4; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: IGIV3I Grifols 10%; Biological
Lead sponsor: Grifols Biologicals, LLC; Industry
Eligibility: 3 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more

Conditions: Atopic Dermatitis
Interventions: Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Fountain Valley, California • San Diego, California + 7 more

Conditions: Ultrasonography, Multiple Trauma, Kidney Calculi, Aortic Aneurysm, Abdominal, Pregnancy, Catheterization, Venous
Interventions: EFAST exam, Pelvic Ultrasound, Ultrasound Guided Vascular Access, Focused Ultrasound Scan, Cardiac Ultrasound; Device · Procedure
Lead sponsor: Keller Fire Rescue; Government
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Keller, Texas

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: educational intervention, Titrated pain management, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 11
States / cities: Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more

Conditions: Chronic Pain
Interventions: StimRouter - active stimulation, StimRouter - Control; Device
Lead sponsor: Bioness Inc; Industry
Eligibility: 22 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 13
States / cities: Scottsdale, Arizona • Napa, California • Pasadena, California + 10 more

Conditions: Multiple Sclerosis, Pain, Fatigue Symptom
Interventions: Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Blood Draw, CSF collection by lumbar puncture (Optional); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Autoimmune Diseases, CNS, Exercise
Interventions: Aerobic exercise, Education Group Control; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acute Renal Failure
Interventions: Renal tubule assist device; Device
Lead sponsor: RenaMed Biologics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 10 more

Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Interventions: Tigulixostat, Allopurinol, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 124
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more

Search by objective public record fields.

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

Dietary Supplements for the Treatment of Angelman Syndrome

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory

Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Thrombosomes® in Bleeding Thrombocytopenic Patients

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Power Over Pain (POP) Study

IGIV Study for Chronic ITP Patients Ages 3-70

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Keller Prehospital Ultrasound Study

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy

Usability of the MeTime MS App

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Aerobic Exercise for Remyelination in Multiple Sclerosis

Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients